The FDA found “unacceptable levels” of a cancer-causing impurity in limited testing using low-heat method of samples of heartburn medicines such as Zantac containing the ingredient ranitidine.
In the wake of the discovery that some Zantac products may contain a carcinogen contaminant due to the manufacturing process, drug store retailers removed the antacid from shelves.
